Literature DB >> 16449315

Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome.

B de Laat1, R H W M Derksen, I J Mackie, M Roest, S Schoormans, B J Woodhams, P G de Groot, W L van Heerde.   

Abstract

BACKGROUND: Annexin A5 is thought to have a role in the pathophysiology of the antiphospholipid syndrome (APS)-a syndrome characterised by recurrent thrombosis and pregnancy morbidity.
OBJECTIVE: To investigate whether anti-annexin A5 immunoglobulin (Ig)M or IgG antibodies, or the -1C-->T polymorphism of annexin A5, is a risk factor for thrombosis or miscarriage, and whether the -1C-->T polymorphism is correlated with APS.
METHODS: A cohort study was carried out with a population of 198 patients with primary APS, systemic lupus erythematosus or lupus-like disease. For the detection of anti-annexin A5 antibodies and the measurement of annexin A5 plasma levels, ELISA-type methods were used. The annexin A5 -1C-->T mutation was detected by restriction fragment length polymorphism.
RESULTS: 71 patients were positive for annexin A5 IgM or IgG antibodies, of whom 53 patients were positive for anti-annexin A5 IgG antibodies and 27 of 198 patients were positive for anti-annexin A5 IgM antibodies. The prevalence of IgM or IgG anti-annexin A5 antibodies was not significantly associated with thrombosis or miscarriage on multivariate analysis. The prevalence of the -1C-->T mutation in the annexin A5 gene (46/198 patients) was significantly associated with miscarriage (odds ratio 2.7, 95% confidence interval 1.1 to 6.7, independent risk factor).
CONCLUSION: The detection of anti-annexin A5 antibodies does not seem relevant for estimating the risk for thrombosis or miscarriage in APS. The -1C-->T mutation was an independent risk factor for miscarriage, which is independent of APS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449315      PMCID: PMC1798354          DOI: 10.1136/ard.2005.045237

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

Review 1.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Authors:  W A Wilson; A E Gharavi; T Koike; M D Lockshin; D W Branch; J C Piette; R Brey; R Derksen; E N Harris; G R Hughes; D A Triplett; M A Khamashta
Journal:  Arthritis Rheum       Date:  1999-07

2.  Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism.

Authors:  J H Rand; X X Wu; H A Andree; C J Lockwood; S Guller; J Scher; P C Harpel
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

3.  [Low prevalence of anti-annexin V antibodies in antiphospholipid syndrome with fetal loss].

Authors:  C Siaka; M Lambert; C Caron; J Amiral; E Hachulla; P Y Hatron; J Goudemand
Journal:  Rev Med Interne       Date:  1999-09       Impact factor: 0.728

4.  Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome.

Authors:  L Lakasing; J S Campa; R Poston; M A Khamashta; L Poston
Journal:  Am J Obstet Gynecol       Date:  1999-07       Impact factor: 8.661

5.  Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.

Authors:  D A Horbach; E van Oort; R C Donders; R H Derksen; P G de Groot
Journal:  Thromb Haemost       Date:  1996-12       Impact factor: 5.249

6.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

7.  beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.

Authors:  H Bas de Laat; Ronald H W M Derksen; Rolf T Urbanus; Mark Roest; Philip G de Groot
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

8.  Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi.

Authors:  J H Rand; X X Wu; S Guller; J Scher; H A Andree; C J Lockwood
Journal:  Am J Obstet Gynecol       Date:  1997-10       Impact factor: 8.661

9.  The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation.

Authors:  G Krikun; C J Lockwood; X X Wu; X D Zhou; S Guller; C Calandri; A Guha; Y Nemerson; J H Rand
Journal:  Placenta       Date:  1994-09       Impact factor: 3.481

10.  Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome.

Authors:  L La Rosa; P L Meroni; A Tincani; G Balestrieri; D Faden; A Lojacono; L Morassi; E Brocchi; N Del Papa; A Gharavi
Journal:  J Rheumatol       Date:  1994-09       Impact factor: 4.666

View more
  14 in total

1.  Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens.

Authors:  Maurizio Bruschi; Maricla Galetti; Renato Alberto Sinico; Gabriella Moroni; Alice Bonanni; Antonella Radice; Angela Tincani; Federico Pratesi; Paola Migliorini; Corrado Murtas; Franco Franceschini; Barbara Trezzi; Francesca Brunini; Rita Gatti; Regina Tardanico; Giancarlo Barbano; Giorgio Piaggio; Piergiorgio Messa; Pietro Ravani; Francesco Scolari; Giovanni Candiano; Alberto Martini; Landino Allegri; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2014-11-14       Impact factor: 10.121

Review 2.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 3.  The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

4.  Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome.

Authors:  Shulan Zhang; Ziyan Wu; Jing Li; Xiaoting Wen; Liubing Li; Wen Zhang; Jiuliang Zhao; Fengchun Zhang; Yongzhe Li
Journal:  Clin Rheumatol       Date:  2016-12-21       Impact factor: 2.980

Review 5.  Plasma Membrane Repair in Health and Disease.

Authors:  Alexis R Demonbreun; Elizabeth M McNally
Journal:  Curr Top Membr       Date:  2015-11-27       Impact factor: 3.049

Review 6.  Genetics of Antiphospholipid Syndrome.

Authors:  Lourdes Ortiz-Fernández; Amr H Sawalha
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

7.  The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Ljudmila Stojanović; Svetlana Ignjatović; Violeta Dopsaj
Journal:  Clin Rheumatol       Date:  2016-03-14       Impact factor: 2.980

Review 8.  Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Authors:  Savino Sciascia; Mary-Carmen Amigo; Dario Roccatello; Munther Khamashta
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

Review 9.  Pathophysiology of the antiphospholipid antibody syndrome.

Authors:  Rohan Willis; Silvia S Pierangeli
Journal:  Auto Immun Highlights       Date:  2011-03-24

10.  Genotyping analysis for the 46 C/T polymorphism of coagulation factor XII and the involvement of factor XII activity in patients with recurrent pregnancy loss.

Authors:  Eriko Asano; Takeshi Ebara; Chisato Yamada-Namikawa; Tamao Kitaori; Nobuhiro Suzumori; Kinue Katano; Yasuhiko Ozaki; Makoto Nakanishi; Mayumi Sugiura-Ogasawara
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.